Life Sciences News | BioTuesdays by Kilmer Lucas IR

Markets

Analysts downgrade ContraFect after DSMB urges Phase 3 MRSA trial end

Analysts for SVB Securities and Maxim Group downgraded ContraFect (NASDAQ:CFRX) after a data safety monitoring board recommended termination for futility of a Phase 3 trial evaluating exebacase in methicillin-resistant...

July 14, 2022

Markets

Dawson James cuts Pluristem to neutral after Phase 3 miss

Dawson James downgraded Pluristem Therapeutics (NASDAQ:PSTI) to “neutral” from “buy” and removed its price target after a Phase 3 trial investigating muscle regeneration following hip surgery did not meet the primary...

July 14, 2022

Developments

Soricimed Biopharma receives additional investment from NBIF

Closely-held Soricimed Biopharma closed a $200,000 investment from the New Brunswick Investment Fund (NBIF) to continue developing its investigational SOR-13 oncology drug candidate. “We are grateful to NBIF for their...

July 13, 2022

Markets

Cantor cuts Humanigen to neutral; PT to $2

Cantor Fitzgerald downgraded Humanigen (NASDAQ:HGEN) to “neutral” from “overweight” and slashed its price target to $2 from $30 after a failed COVID-19 study. The stock closed at $2.99 on July 12. The National Institute...

July 13, 2022

Markets

Stifel cuts Atara Biotherapeutics to hold; PT to $5

Stifel downgraded Atara Biotherapeutics (NASDAQ:ATRA) to “hold” from “buy” and lowered its price target to $5 from $16, following the company’s interim Phase 2 analysis with ATA188 for the treatment of multiple...

July 13, 2022

Markets

AGP cuts OpGen to neutral; PT to 67 cents

Alliance Global Partners downgraded OpGen (NASDAQ:OPGN) to “neutral” and lowered its price target to 67 cents, citing the company’s cash needs. The stock closed at 61 cents on July 11. “We view the company’s...

July 12, 2022

Developments

Rhythm Pharma posts positive Phase 2 data in hypothalamic obesity

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported positive interim results from a Phase 2 clinical trial evaluating setmelanotide, its MC4R agonist, for the treatment of severe obesity and hyperphagia in people living with...

July 12, 2022

Developments

Eupraxia Pharma receives emerging life sciences award for 2022 in B.C.

Eupraxia Pharmaceuticals (TSX:EPRX) received the Emerging Life Sciences Company Award of the year from Life Sciences British Columbia. In a statement, Dr. James Helliwell, CEO of Eupraxia, said that following a...

July 9, 2022

Markets

AGP cuts T2 Biosystems to neural; PT to 14 cents

Alliance Global Partners downgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “buy” and reduced its price target to 14 cents from 65 cents, citing a fiscal second quarter preliminary revenue miss. The stock was...

July 7, 2022

Developments

Annovis Bio gets FDA okay for Phase 3 Parkinson’s trial

Annovis Bio, Inc. (NYSE:ANVS) received notice from the FDA that a Phase 3 clinical study with buntanetap in early Parkinson’s patients may proceed. The FDA accepted the final protocol and the clinical development...

July 7, 2022

Markets

Echelon starts Mindset Pharma at speculative buy; PT $1.35 (Canadian)

Echelon Capital Markets initiated coverage of Mindset Pharma (CSE:MSET) with a “speculative buy” rating and price target of $1.25 (Canadian). The stock closed at 33 cents on July 6. Mindset develops patented psychedelic...

July 7, 2022

Markets

WB starts POINT Biopharma at outperform

William Blair initiated coverage of POINT Biopharma Global (NASDAQ:PNT) with an “outperform” rating based on a view that the Street is “underestimating the clinical and commercial potential of the company’s...

July 6, 2022

Analysts downgrade ContraFect after DSMB urges Phase 3 MRSA trial end

Dawson James cuts Pluristem to neutral after Phase 3 miss

Soricimed Biopharma receives additional investment from NBIF

Cantor cuts Humanigen to neutral; PT to $2

Stifel cuts Atara Biotherapeutics to hold; PT to $5

AGP cuts OpGen to neutral; PT to 67 cents

Rhythm Pharma posts positive Phase 2 data in hypothalamic obesity

Eupraxia Pharma receives emerging life sciences award for 2022 in B.C.

AGP cuts T2 Biosystems to neural; PT to 14 cents

Annovis Bio gets FDA okay for Phase 3 Parkinson’s trial

Echelon starts Mindset Pharma at speculative buy; PT $1.35 (Canadian)

WB starts POINT Biopharma at outperform

General

More